Overview

Effect of Evolocumab Added to Moderate-Intensity Statin Therapy on LDL-C Lowering and Cardiovascular Adverse Events in Patients With Acute Coronary Syndrome

Status:
Recruiting

Trial end date:
2023-06-01

Target enrollment:

Participant gender:

Summary

The study is an open-label, multicenter, and randomized study(five hospitals).The purpose of this study is to assess the differences in the effects of the evolocumab added to moderate-intensity statin therapy and the moderate-intensity statin only therapy on the regulation of LDL-C levels in patients with acute phase acute coronary syndrome after four weeks of treatment. The primary outcome is the percentage change in LDL-C in weeks 4 and week 12 after treatment. The secondary outcome is the occurrence of MACE after 12 weeks and 1 year of treatment.

Phase:

Phase 4

Details

Lead Sponsor:

Tianjin Chest Hospital

Treatments:

Antibodies, Monoclonal
Evolocumab
Hydroxymethylglutaryl-CoA Reductase Inhibitors